Zacks Analyst Blog Highlights: Quilmes Industrial, AmBev, Merck & Co. and CONMED Corp.CHICAGO -- Zacks.com announces the list of stocks featured in the Analyst Blog. Every day, the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include: Quilmes Industrial (NYSE NYSE See: New York Stock Exchange :LQU), AmBev (NYSE:ABV ABV Above ABV Alcohol By Volume ABV Abuja, Nigeria (airport code) ABV Assault Breacher Vehicle ABV Accredited Business Valuation specialist ABV Auxiliary Building Ventilation ABV Annual Buy Value ABV Air Bleed Valve ), Merck & Co. (NYSE:MRK MRK Merck & Company (stock symbol) MRK Mayer-Rokitansky-Kuster (anomaly) MRK Manual Remote Keying ) and CONMED Corp. (Nasdaq:CNMD). See the latest posts to the Analyst Blog by visiting: http://at.zacks.com/?id=2673 Here are highlights from Tuesday's Analyst Blog: Upping Quinsa to Buy Quilmes Industrial (Quinsa, NYSE:LQU), S.A. is a beneficiary of the recovering economies in Latin America Latin America, the Spanish-speaking, Portuguese-speaking, and French-speaking countries (except Canada) of North America, South America, Central America, and the West Indies. . In addition, the synergies from the alliance of operations with AmBev (NYSE:ABV) have become apparent from the company's latest financial reports. Most recently, AmBev increased its ownership of Quinsa to 91%, effectively controlling the company. Ultimately, public shareholders most probably will be bought out. Given the improving fundamentals and the Stock's recent pullback Pullback A falling back of a price from its peak. This type of price movement might be seen as a brief reversal of the prevailing upward trend, signaling a slight pause in upward momentum. , Quinsa is upgraded to a Buy. Merck Raised to Hold We are upgrading the rating on Merck & Co. (NYSE:MRK) from Sell to Hold after the solid second quarter financial results. The company has been able to successfully return to growth given the launch of four new vaccine products. Sales of existing drugs are tracking on plan, with earnings upside being driven by sales of the cholesterol franchise drugs Zetia and Vytorin. However, Merck's Zocor lost patent protection at the end of June 2006, and there are some 14,200 Vioxx lawsuits. Merck's stock has risen almost 50% so far this year. We think the name is fairly valued. Our price target is now $40 per share. Weakness at CONMED CONMED Corp. (Nasdaq:CNMD) reported second quarter pro forma As a matter of form or for the sake of form. Used to describe accounting, financial, and other statements or conclusions based upon assumed or anticipated facts. The phrase pro forma EPS (Encapsulated PostScript) A PostScript file format used to transfer a graphic image between applications and platforms. EPS files contain PostScript code as well as an optional preview image in TIFF, WMF, PICT or EPSI, the latter being an ASCII-only format. of $0.23, beating our estimates by two cents on better-than-expected revenues. Arthroscopy Arthroscopy Definition Arthroscopy is the examination of a joint, specifically, the inside structures. The procedure is performed by inserting a specifically designed illuminated device into the joint through a small incision. segment revenues, especially video imaging cameras that rose 23%, contributed to the revenue upside. We are raising our pro forma 2007 estimates on continued margin improvement. However, we continue to believe the company is losing some share in its markets, as powered instruments remain weak. At roughly an in-line 1.2x P/E/G on our 2007 EPS with a long-term 11% growth outlook, or 13x 2007 EPS, our target moves to $18.00. See the latest posts to the Analyst Blog by visiting http://at.zacks.com/?id=2645 About Zacks Equity Research Zacks Equity Research provides the best of quantitative and qualitative analysis Qualitative Analysis Securities analysis that uses subjective judgment based on nonquantifiable information, such as management expertise, industry cycles, strength of research and development, and labor relations. to help investors know what stocks to buy and which to sell for the long-term. Continuous coverage is provided for a universe of 1,150 publicly traded stocks. Our analysts are organized by industry which gives them keen insights to developments that affect company profits and stock performance. Recommendations and target prices are six-month time horizons. Zacks "Profit from the Pros" e-mail newsletter provides highlights of the latest analysis from Zacks Equity Research. Subscribe to Verb 1. subscribe to - receive or obtain regularly; "We take the Times every day" subscribe, take buy, purchase - obtain by purchase; acquire by means of a financial transaction; "The family purchased a new car"; "The conglomerate acquired a new company"; this free newsletter today by visiting http://at.zacks.com/?id=2674. About Zacks Zacks.com is a property of Zacks Investment Research Zacks Investment Research A firm that compiles earnings estimates and brokerage firm investment recommendations for thousands of publicly traded firms. , Inc., which was formed in 1978 by Leonard Zacks. As a PhD in mathematics Len knew he could find patterns in stock market data that would lead to superior investment results. Amongst his many accomplishments was the formation of his proprietary stock picking system; the Zacks Rank, which continues to outperform the market by nearly a 3 to 1 margin. The best way to unlock the profitable stock recommendations and market insights of Zacks Investment Research is through our free daily email newsletter; Profit from the Pros. In short, it's your steady flow of Profitable ideas GUARANTEED to be worth your time! Register for your free subscription to Profit from the Pros. |
|
||||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion